Answers are grounded in this paper and cite their sources.
BACKGROUND: Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important curative treatment for pediatric patients with SAA. The chimeric anti-CD20 monoclonal antibody rituximab (RTX) is the most widely used agent to deplete circulating B cells for preventing the complication of donor-specific human leukocyte antigen antibodies and treating Epstein-Barr virus (EBV) reactivation in patients who undergo allo-HSCT. However, RTX efficacy and safety in allo-HSCT recipients with SAA remain unclear in pediatric patients. METHODS: This study included 105 pediatric patients with SAA who underwent allo-HSCT at Wuhan Children's Hospital. The patients' basic characteristics, stem cell transplantation, survival, GVHD occurrence, CMV and EBV reactivation and amounts of lymphocytes was compared in the patients with RTX (RTX+) and without RTX (RTX-) treatment. RESULTS: Compared with the RTX-, the RTX+ showed a significantly higher incidence of GVHD (16.6% vs 4%; P = 0.02). The RTX+ was associated with a markedly higher rate of CMV reactivation (76.7% vs 38.7%; P < 0.001) and lower rate of EBV reactivation (60.0% vs 89.3%; P < 0.001). Among 1 month after HSCT, the RTX+ exhibited lower T-cell (P = 0.04), B-cell (P < 0.001), and NK-cell (P = 0.01) counts, which exhibit no significant difference in the long-term period. CONCLUSION: The pre-treatment of RTX exhibits beneficial effects on the overall and long-term response, indicated by 100% successful implantation, lower risk of EBV reactivation, and little influence on lymphocyte regeneration. More emphasis should be placed on preventing CMV reactivation among RTX-treated pediatric SAA patients undergoing allo-HSCT.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: